A detailed history of Boothbay Fund Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 1,703 shares of KRYS stock, worth $334,673. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,703
Previous 9,700 82.44%
Holding current value
$334,673
Previous $1.78 Million 82.65%
% of portfolio
0.01%
Previous 0.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$174.7 - $213.66 $297,514 - $363,862
1,703 New
1,703 $309,000
Q3 2019

Nov 14, 2019

SELL
$34.72 - $51.3 $301,543 - $445,540
-8,685 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$27.2 - $41.2 $236,232 - $357,822
8,685 New
8,685 $350,000
Q1 2019

May 15, 2019

SELL
$19.86 - $32.9 $199,354 - $330,250
-10,038 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$15.03 - $25.38 $150,871 - $254,764
10,038 New
10,038 $209,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $5.04B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.